Evidence map›Paper›PMID 36103050›Full record

ReviewAmerican journal of clinical dermatology2022

Cutaneous Leishmaniasis: A 2022 Updated Narrative Review into Diagnosis and Management Developments.

Henry J C de Vries, Henk D Schallig

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in American journal of clinical dermatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 205 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
205citing papers in PubMed, 10 pooled it
55.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

205 citing papers in PubMed, 10 syntheses or guidelines pooled it, 310 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. An Intriguing, Solitary Nodule on the Nose.Indian dermatology online journal · 2026
    Article
  18. Review
  19. In Silico Screening ofBiology · 2026
    Article
  20. Cluster of imported cutaneous leishmaniasis due toEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026
    Article

145 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Henry J C de VriesDepartment of Dermatology, Amsterdam UMC Location University of Amsterdam, Meibergdreef 9, P.O. Box 22700, 1100 DE, Amsterdam, The Netherlands. h.j.devries@amc.nl.ORCID http://orcid.org/0000-0001-9784-547X
Henk D SchalligAmsterdam Institute for Infection and Immunology, Infectious Diseases, Amsterdam, The Netherlands.
Amsterdam University Medical Centers · NLNetherlands Center for Occupational Diseases · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This review is an update of an earlier narrative review published in 2015 on developments in the clinical management of cutaneous leishmaniasis (CL) including diagnosis, treatment, prevention and control measurements. CL is a vector-borne infection caused by the protozoan parasite Leishmania. The vector is the female sandfly. Globally, CL affects 12 million cases and annually 2 million new cases occur. CL is endemic in almost 100 countries and the total risk population is approximately 350 million people. WHO lists CL an emerging and uncontrolled disease and a neglected tropical disease. Local experience-based evidence remains the mainstay for the management of CL. Whereas intralesional therapeutic options are the first treatment option for most CL patients, those with mucocutaneous and disseminated involvement require a systemic therapeutic approach. Moreover, different Leishmania species can vary in their treatment outcomes. Therefore, species determination is critical for optimal CL clinical management. New DNA techniques allow for relatively easy Leishmania species determination, yet they are not easily implemented in resource-limited settings. There is a desperate need for novel, less toxic, and less painful treatment options, especially for children with CL. Yet, the large and well conducted studies required to provide the necessary evidence are lacking. To further control and potentially eliminate CL, we urgently need to improve vector control, and diagnostics, and we require efficient and safe vaccines. Alas, since CL primarily affects poor people, biotechnical companies dedicate little investment into the research programs that could lead to diagnostic, pharmaceutical, and vaccine innovations.

Indexed as

Leishmaniasis, CutaneousChildFemaleHumansPharmaceutical PreparationsPharmaceutical Preparations

Identifiers

PMID36103050
PMCPMC9472198
OpenAlexW4295759702

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.